HMGB1
ENSG00000189403
Target class
Unclassified protein
Chromosome
13
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- HMGB1
- Gene name
- High mobility group box 1
- Gene symbol
- HMGB1
- Previous gene symbols
- HMG1
- Protein name
- High mobility group protein B1 (High mobility group protein 1) (HMG-1)
- HMG3
- SBP-1
- DKFZp686A04236
- Gene biotype
- Protein coding
- Gene family
- Canonical high mobility group
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 136.13
- Tissue specificity (Gini)
- 0.247
- Tissue specificity (tau)
- 0.505
- KEGG gene identifiers
- hsa:3146
- Protein interaction confidence
- 0.8501
- Protein interaction partners
- 60
- R-HSA-1236974
- R-HSA-140342
- R-HSA-166058
- R-HSA-3000471
- R-HSA-445989
- R-HSA-5602498
- R-HSA-5603041
- R-HSA-5620971
- R-HSA-5686938
- R-HSA-6798695
- R-HSA-879415
- R-HSA-933542
- End position
- 30618872
- Start position
- 30456704
- Chromosome
- 13
- Strand
- Reverse
- Nucleus . Chromosome . Cytoplasm . Secreted . Cell membrane
- Peripheral membrane protein
- Extracellular side . Endosome . Endoplasmic reticulum-Golgi intermediate compartment . Note=In basal state predominantly nuclear. Shuttles between the cytoplasm and the nucleus (PubMed:12231511, PubMed:17114460). Translocates from the nucleus to the cytoplasm upon autophagy stimulation (PubMed:20819940). Release from macrophages in the extracellular milieu requires the activation of NLRC4 or NLRP3 inflammasomes (By similarity). Passively released to the extracellular milieu from necrotic cells by diffusion, involving the fully reduced HGMB1 which subsequently gets oxidized (PubMed:19811284). Also released from apoptotic cells (PubMed:16855214, PubMed:18631454). Active secretion from a variety of immune and non-immune cells such as macrophages, monocytes, neutrophils, dendritic cells and natural killer cells in response to various stimuli such as LPS and cytokines involves a nonconventional secretory process via secretory lysosomes (PubMed:12231511, PubMed:14532127, PubMed:15944249). Secreted by plasma cells in response to LPS (By similarity). Found on the surface of activated platelets (PubMed:11154118). An increased chromatin association is observed when associated with the adenovirus protein pVII (PubMed:27362237). .
- SUBCELLULAR LOCATION: Endoplasmic reticulum . Note=(Microbial infection) SARS-COV-2 ORF3A promotes HMGB1 translocation from the nucleus to the cytoplasm where it is recruited by and colocalizes with ORF3A at the endoplasmic reticulum. .
- Nucleoplasm
- PubMed 12231511
- PubMed 17114460
- PubMed 20819940
- PubMed 22696656
- PubMed 22869893
- PubMed 27362237
- PubMed 29618516
- PubMed 33147444
- PubMed 11154118
- PubMed 34971702
- PubMed 14532127
- PubMed 15944249
- PubMed 19811284
- PubMed 16855214
- PubMed 18631454
- PubMed 20123072
- PubMed 35239449
- Tissue specificity (tau)
- 0.505198
- Expression inequality (Gini)
- 0.247303
Expression in transcripts per million
- Uterus
- 136.13
- Cervix - Ectocervix
- 133.3
- Cervix - Endocervix
- 129.3
- Cells - EBV-transformed lymphocytes
- 122.66
- Fallopian Tube
- 122.35
Expression in transcripts per million
- Uterus136.13
- Cervix - Ectocervix133.3
- Cervix - Endocervix129.3
- Cells - EBV-transformed lymphocytes122.66
- Fallopian Tube122.35
- Nerve - Tibial114.85
- Artery - Tibial108.91
- Ovary101.3
- Brain - Cerebellar Hemisphere95.11
- Vagina93.43
- Thyroid93.27
- Artery - Aorta90.22
- Adipose - Subcutaneous89.46
- Breast - Mammary Tissue88
- Artery - Coronary87.9
- Colon - Sigmoid85.23
- Brain - Spinal cord (cervical c-1)82.31
- Bladder81.02
- Lung80.34
- Prostate79.14
- Cells - Cultured fibroblasts76.7
- Spleen76.28
- Esophagus - Gastroesophageal Junction74.11
- Small Intestine - Terminal Ileum73.62
- Brain - Cerebellum72.49
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0002218
- GO:0002437
- GO:0002643
- GO:0006954
- GO:0007204
- GO:0010508
- GO:0017055
- GO:0031507
- GO:0032425
- GO:0032689
- GO:0032732
- GO:0032733
- GO:0032735
- GO:0032755
- GO:0032757
- GO:0032760
- GO:0033151
- GO:0035711
- GO:0042104
- GO:0043065
- GO:0043277
- GO:0043371
- GO:0043388
- GO:0043410
And 13 more, listed on the interactive page.
- GO:0000793
- GO:0005576
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005783
- GO:0005886
- GO:0009986
- GO:0017053
- GO:0034774
- GO:0035868
- GO:1904813
- GO:0000976
- GO:0001530
- GO:0001786
- GO:0003684
- GO:0003713
- GO:0003714
- GO:0003723
- GO:0005178
- GO:0005515
- GO:0008301
- GO:0016829
- GO:0019958
- GO:0048018
- GO:0061629
- GO:0070182
- GO:0140297
- GO:0140656
Related records
Trials (1,406)
- "Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy"
- [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 2-week dc of MTX and Influenza Vaccination in RA
- 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
- 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
- 506U78 in Treating Patients With Refractory Hematologic Cancer
- A 30-month Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate in Erosive Hand OA.
- A Bioavailability Study of Methotrexate 25 mg Administered by Needle Injection and a Pre Filled Needle-free Device in Healthy Volunteers.
- A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
- A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy
- A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
- A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）
- A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
- A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours
- A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
- A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
- A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects
- A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
- A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.
Drugs (2)
- CD24FC High mobility group protein B1 inhibitor
- Methotrexate